{"id":"botox-infiltration","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site pain or bruising"},{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Muscle weakness or paralysis (unintended muscles)"},{"rate":"1-3","effect":"Ptosis (eyelid drooping)"},{"rate":"1-5","effect":"Dry mouth or dry eye"},{"rate":"1-3","effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Botox (botulinum toxin type A) cleaves SNARE proteins required for acetylcholine vesicle release, preventing muscle contraction in the infiltrated area. This results in temporary muscle relaxation lasting 3-4 months. The effect is localized to the injection site and gradually reverses as new neuromuscular junctions form.","oneSentence":"Botulinum toxin blocks acetylcholine release at the neuromuscular junction, causing temporary paralysis of injected muscles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:46.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle hyperactivity disorders (cervical dystonia, blepharospasm, hemifacial spasm)"},{"name":"Chronic migraine"},{"name":"Spasticity"},{"name":"Cosmetic wrinkle reduction (glabellar lines, crow's feet, forehead lines)"}]},"trialDetails":[{"nctId":"NCT07034547","phase":"NA","title":"Effect of Botulinum Toxin Type A on Motor Function in Children With Cerebral Palsy","status":"RECRUITING","sponsor":"Instituto Teletón Chile","startDate":"2025-06-11","conditions":"Cerebral Palsy (CP), Spasticity Due to Cerebral Palsy, Hemiparesis","enrollment":30},{"nctId":"NCT06530524","phase":"PHASE2","title":"Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2024-10-01","conditions":"Head Neck Cancer, Xerostomia Following Radiotherapy","enrollment":50},{"nctId":"NCT06036043","phase":"","title":"Botulinum Toxin for Chronic Neuropathic Pain","status":"UNKNOWN","sponsor":"Region Zealand","startDate":"2023-08-01","conditions":"Neuralgia, Chronic Pain","enrollment":12},{"nctId":"NCT04595045","phase":"PHASE3","title":"Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis","status":"COMPLETED","sponsor":"Aránzazu Vázquez Doce","startDate":"2019-01-24","conditions":"Multiple Sclerosis","enrollment":84},{"nctId":"NCT05151874","phase":"","title":"Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2022-01","conditions":"Spasticity, Muscle, Stroke Sequelae, Movement Disorders","enrollment":12},{"nctId":"NCT02784262","phase":"PHASE2","title":"Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-10","conditions":"Chronic Disease, Nasal Polyposis, Rhinitis","enrollment":11},{"nctId":"NCT04750291","phase":"PHASE4","title":"Management of Popeye Sign With Botulinum Toxin After Bicepstenotomy","status":"UNKNOWN","sponsor":"AZ Delta","startDate":"2021-08-09","conditions":"Popeye Syndrome","enrollment":20},{"nctId":"NCT03054610","phase":"PHASE1","title":"Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.","status":"COMPLETED","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2015-01","conditions":"Plantar Fascitis, Botulinum Toxins, Type A","enrollment":60},{"nctId":"NCT02078791","phase":"PHASE4","title":"Discomfort and Psychosocial Difficulties in Fibromyalgia","status":"COMPLETED","sponsor":"University Rovira i Virgili","startDate":"2012-07","conditions":"Fibromyalgia","enrollment":66},{"nctId":"NCT01489904","phase":"PHASE2, PHASE3","title":"Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy","status":"UNKNOWN","sponsor":"Hospital Vall d'Hebron","startDate":"2011-11","conditions":"Sialorrhea, Cerebral Palsy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["botox infiltration, and grup solving terapy group"],"phase":"marketed","status":"active","brandName":"Botox infiltration","genericName":"Botox infiltration","companyName":"University Rovira i Virgili","companyId":"university-rovira-i-virgili","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum toxin blocks acetylcholine release at the neuromuscular junction, causing temporary paralysis of injected muscles. Used for Muscle hyperactivity disorders (cervical dystonia, blepharospasm, hemifacial spasm), Chronic migraine, Spasticity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}